Top Markets
Coin of the day
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
Kedudukan dalam Saham #27
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery,... AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behรงet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Harga Saham
$263.25
Modal Pasaran
$465.10B
Perubahan (1 hari)
-0.68%
Perubahan (1 tahun)
18.26%
Negara
US
Perdagangan AbbVie Inc. (ABBV)

Kategori

EPS untuk AbbVie Inc. (ABBV)
EPS setakat June 2026 TTM: $3.55
Menurut laporan kewangan terkini dan harga saham AbbVie Inc., EPS semasa syarikat (TTM) adalah $3.55. Pada akhir tahun 2024, syarikat mempunyai EPS sebanyak $2.40 penurunan berbanding EPS tahun 2023 iaitu $2.73.
Sejarah EPS untuk AbbVie Inc. dari 2009 hingga 2026
EPS pada akhir setiap tahun
Tahun EPS Ubah
2026 (TTM) $3.55 49.16%
2025 $2.38 -0.83%
2024 $2.40 -12.09%
2023 $2.73 -58.95%
2022 $6.65 2.62%
2021 $6.48 137.36%
2020 $2.73 -48.49%
2019 $5.30 43.63%
2018 $3.69 11.48%
2017 $3.31 -9.32%
2016 $3.65 15.87%
2015 $3.15 183.78%
2014 $1.11 -56.98%
2013 $2.58 -22.99%
2012 $3.35 58.02%
2011 $2.12 -18.15%
2010 $2.59 -9.76%
2009 $2.87 0.00%
EPS untuk syarikat atau pesaing yang serupa
Syarikat EPS Perbezaan EPS Negara
$29.89 741.97%
US
$8.65 143.66%
US
$20.39 474.34%
CH
$1.26 -64.51%
US
$7.19 102.54%
CH